Treats molluscum contagiosum (MC). Sold as Zelsuvmi. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Berdazimer Sodium (sold as Zelsuvmi), first approved Jan 5, 2024, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Zelsuvmi | Part D | $49K | New | 18 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
